{"id":"NCT01857323","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)","officialTitle":"A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05","primaryCompletion":"2013-08","completion":"2013-09","firstPosted":"2013-05-20","resultsPosted":"2015-06-08","lastUpdate":"2015-06-08"},"enrollment":317,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma","Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Albuterol Spiromax®","otherNames":["ProAir® RespiClick, Albuterol multi-dose dry powder inhaler (MDPI)"]}],"arms":[{"label":"Albuterol Spiromax®","type":"EXPERIMENTAL"}],"summary":"This is a prospective, open-label, multicenter Phase 3 study evaluating the performance of the Albuterol Spiromax dose counter in patients with a diagnosis of asthma and/or COPD. The purpose of this study is to evaluate the functionality, reliability, and accuracy of the Albuterol Spiromax inhaler integrated dose counter in a clinical setting.","primaryOutcome":{"measure":"Dosing Discrepancies Per 200 Dose Cycles: Dose Cycle Not Count","timeFrame":"Day 1 - Day 50","effectByArm":[{"arm":"Albuterol Spiromax®","deltaMin":2.05,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":["26831652"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":316},"commonTop":["Headache","Sinusitis"]}}